OriCiro Genomics is a pioneer in cell-free synthesis and amplification of genome-scale large DNA for synthetic biology. OriCiro focuses on the development and commercialization of cell-free synthesis and amplification technologies of large DNA molecules. One of the company’s proprietary technologies enables cell-free amplification of large DNA molecules, an efficient and easy-to- operate approach that aims to replace conventional E. coli cloning. It can not only streamline current research processes but also widen the scope of genomics research significantly. In addition to the amplification technology, the company owns a suite of genome manipulation technologies including the assembly of DNA fragments and genome editing. Synthetic biology, an emerging field in life sciences in which new medicines and useful proteins are produced more efficiently by modified and/or synthesized genomes, is developing rapidly worldwide with ever-increasing industrial applications. OriCiro’s technologies have potential markets in a variety of industrial sectors including the pharmaceutical, diagnostic, food and agricultural sectors, it being a powerful tool for research and development aimed at unlocking the possibility of synthetic biology.